The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Abstract
IMPORTANCE: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. OBJECTIVE: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. EXPOSURE: Ipilimumab therapy. MAIN OUTCOMES AND MEASURES: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. RESULTS: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Possible risk factors for ICI-related hepatotoxicity include organ transplantation, comorbidity with autoimmune disease, history of ICI-induced irAEs, high doses of ICIs (particularly cytotoxic T-lymphocyte antigen 4 inhibitors), combination therapy with multiple ICIs, or a combination of an ICI with targeted therapy [165][166][167].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [165]
In the citing paper
“Incidence of endocrine events varies based on type of ICI used (see Figure 2).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“hypophysitis or hypopituitarism occurs in up to 10% of patients who receive anti-CTLA-4 based therapy (either with ipilimumab monotherapy, and slightly more commonly with combination CTLA-4/PD-1 blockade).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationSchneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,498
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
“Two out of six patients with CD or UC had ipilimumab-induced colitis or a relapse of UC or CD [39].”
BackgroundAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Dávila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,296
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,396
Immune checkpoint inhibitors in melanoma
Carlino, M. S., Larkin, J., & Long, G. V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01206-x · Cited by 1,235
Self-citationImmune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Self-citationBrahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Self-citationMenzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817
Self-citationKumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 640
Dermatologic Reactions to Immune Checkpoint Inhibitors
Sibaud, V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0336-3 · Cited by 640
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Self-citationAbdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
Axelrad, J. E., Lichtiger, S., & Yajnik, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i20.4794 · Cited by 431
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Self-citationCappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Self-citationHassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T., Grimm, M., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 334
Self-citationMa, W., Gilligan, B. M., Yuan, J. D., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 333
Lozano, A. X., Chaudhuri, A. A., Nene, A., Bacchiocchi, A., Earland, N. J., Vesely, M. D., Usmani, A., Turner, B. E., Steen, C. B., Luca, B. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01623-z · Cited by 323
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, É., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 317
Danlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.008 · Cited by 300
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307
Castillo, M. D., Romero, F. A. R., Argüello, E., Kyi, C., Postow, M. A., & Redelman‐Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 292
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
Graus, F., & Dalmau, J. O. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0194-4 · Cited by 292
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Peeraphatdit, T. (., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R. (2020) · Hepatology · doi:10.1002/hep.31227 · Cited by 264
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 282
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, V., Meyer, N., Lamant, L., Vigarios, É., Mazières, J., & Delord, J. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000290 · Cited by 269
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, É., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D. M., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 267
Rini, B. I., Battle, D. J., Figlin, R. A., George, D. J., Hammers, H. J., Hutson, T., Jonasch, E. W., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 259
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A. A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 250
Belkhir, R., Burel, S. L., Dunogeant, L., Marabelle, A., Hollebecque, A., Besse, B., Leary, A. F., Voisin, A.-L., Pontoizeau, C., Coutte, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211216 · Cited by 245
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 243
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Pinter, M., Scheiner, B., & Peck‐Radosavljevic, M. (2020) · Gut · doi:10.1136/gutjnl-2020-321702 · Cited by 238
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 237
Pelly, V. S., Moeini, A., Roelofsen, L. M., Bonavita, E., Bell, C. R., Hutton, C., Blanco‐Gómez, A., Banyard, A., Bromley, C. P., Flanagan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1815 · Cited by 230
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 234
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Self-citationHusebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C., Lupi, I., Paschou, S. Α., Tóth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 216
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0618 · Cited by 208
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Abu‐Sbeih, H., Faleck, D. M., Ricciuti, B., Mendelsohn, R. B., Naqash, A. R., Cohen, J. V., Sellers, M. C., Balaji, A., Ben‐Betzalel, G., Ibraheim, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01674 · Cited by 209
Self-citationGutzmer, R., Koop, A., Meier, F. E., Hassel, J. C., Terheyden, P. A. M., Zimmer, L., Heinzerling, L., Ugurel, S., Pföhler, C., Gesierich, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.038 · Cited by 205
Self-citationBurel, S. L., Champiat, S., Mateus, C., Marabelle, A., Michot, J., Robert, C., Belkhir, R., Soria, J., Laghouati, S., Voisin, A.-L., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.032 · Cited by 203
Neurological toxicities associated with immune-checkpoint inhibitors
Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000503 · Cited by 204
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200
Calabrese, C. M., Kirchner, E., Kontzias, A., Velcheti, V., & Calabrese, L. H. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000412 · Cited by 201
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Tison, A., Garaud, S., Chiche, L., Cornec, D., & Kostine, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00841-0 · Cited by 204
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L., Hohlfeld, R., & Liblau, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 178
Dalakas, M. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418799864 · Cited by 177
Yoest, J. M. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 175
Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171
Current prospects of type II interferon γ signaling and autoimmunity
Green, D. S., Young, H. A., & Valencia, J. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.774745 · Cited by 181
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 171
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
Cramer, P., & Bresalier, R. S. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0540-6 · Cited by 167
Prevalence of Autoimmune Disease Among Patients With Lung Cancer
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2238 · Cited by 164
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
Poels, K., van Leent, M. M. T., Boutros, C., Tissot, H., Roy, S., Meerwaldt, A. E., Toner, Y. C., Reiche, M. E., Kusters, P. J. H., Malinova, T. S., et al. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.08.007 · Cited by 162
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 154
Immune Checkpoint Inhibitors in Organ Transplant Patients
Kittai, A. S., Oldham, H., Cetnar, J., & Taylor, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000180 · Cited by 151
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 151
Katsuya, Y., Horinouchi, H., Seto, T., Umemura, S., Hosomi, Y., Satouchi, M., Nishio, M., Kozuki, T., Hida, T., Sukigara, T., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.012 · Cited by 149
Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 152
Self-citationFarina, A., Villagrán‐García, M., Vogrig, A., Ζεκερίδου, Α., Muñiz‐Castrillo, S., Velasco, R., Guidon, A. C., Joubert, B., & Honnorat, J. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00369-1 · Cited by 160
Richter, M. D., Crowson, C. S., Kottschade, L. A., Finnes, H. D., Markovic, S. N., & Thanarajasingam, U. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40745 · Cited by 148
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 147
Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1202st · Cited by 143
Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa
Kim, J. H., & Kim, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01259 · Cited by 141
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Tang, L., Wang, J., Lin, N., Zhou, Y., He, W., Liu, J., & Ma, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800879 · Cited by 139
Drug-induced lupus: Traditional and new concepts
Vaglio, A., Grayson, P. C., Fenaroli, P., Gianfreda, D., Boccaletti, V., Ghiggeri, G. M., & Moroni, G. L. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.03.016 · Cited by 131
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
Geller, S., Xu, H., Lebwohl, M., Nardone, B., Lacouture, M. E., & Kheterpal, M. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0337-2 · Cited by 127
Redelman‐Sidi, G., Michielin, O. A., Cervera, C., Ribi, C., Aguado, J. M., Fernández‐Ruiz, M., & Manuel, O. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.030 · Cited by 127
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Self-citationCTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Yshii, L., Gebauer, C., Pignolet, B., Mauré, E., Queriault, C., Pierau, M., Saito, H., 昇, 鈴., Brunner-Weinzierl, M. C., Bauer, J., et al. (2016) · Brain · doi:10.1093/brain/aww225 · Cited by 123
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
For the German Dermatologic Cooperative Oncology Group (DeCOG), Kähler, K. C., Eigentler, T., Gesierich, A., Heinzerling, L., Loquai, C., Meier, F. E., Meiß, F., Pföhler, C., Schlaak, M. S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2134-z · Cited by 123
Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez-Almazor, M. E., Kim, S. T., Abdel‐Wahab, N., & Diab, A. K. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40043 · Cited by 122
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 123
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Self-citationImmune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 118
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 117
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Chang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 119
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 118
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Richter, M. D., Pinkston, O., Kottschade, L. A., Finnes, H. D., Markovic, S. N., & Thanarajasingam, U. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40397 · Cited by 115
Multiple sclerosis outcomes after cancer immunotherapy
García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 117
Toxicities associated with checkpoint inhibitors—an overview
Spiers, L., Coupe, N. A., & Payne, M. (2019) · Rheumatology · doi:10.1093/rheumatology/kez418 · Cited by 112
Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z. R., Murgoi, P., & Vuong, T. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.009 · Cited by 111
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J. M., Sosman, J. A., Long, G. V., & Clark, J. I.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- The University of Sydney (AU)
- Roswell Park Comprehensive Cancer Center (US)
- Rutgers Cancer Institute (US)
- University Hospital Heidelberg (DE)
- Westmead Hospital (AU)
- Loyola University Medical Center (US)
- Corresponding author
- Johnson, Douglas B.
- ORCID
- Johnson, Douglas B.
- Sullivan, Ryan J.
- Ott, Patrick A.
- Carlino, Matteo S.
- Khushalani, Nikhil I.
- Ye, Fei
- Guminski, Alexander
- Puzanov, Igor
- Lawrence, Donald P.
- Buchbinder, Elizabeth I.
- Spencer, Kristen
- Bender, Carolin
- Lee, Jenny
- Kaufman, Howard L.
- Menzies, Alexander M.
- Hassel, Jessica C.
- Mehnert, Janice M.
- Sosman, Jeffrey A.
- Long, Georgina V.
- Clark, Joseph I.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 2
- Issue
- 2
- Pages
- 234
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2193769500
- Cited by
- 642
- References
- 30
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 49 · 2023: 44 · 2022: 64 · 2021: 73 · 2020: 94 · 2019: 93 · 2018: 65 · 2017: 68 · 2016: 47
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K12 CA 0906525, K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, advanced melanoma, immune-related adverse events, immune-related colitis, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related dermatitis, immune checkpoint inhibitors, immunosuppressive therapy, rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Female, Humans, Male, Melanoma, Middle Aged, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Autoimmunity, Treatment Outcome, Risk Assessment, Patient Selection, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
